Interim Report January – June 2018
Positive results of the BAN2401 Phase 2b study in early Alzheimer’s disease April – June 2018 · Net revenues for the period amounted to SEK 52.3 million (32.0) · Operating profit amounted to SEK 6.4 million (2.5) · Profit for the period amounted to SEK 5.1 million (2.3) · Earnings per share were SEK 0.06 (0.04) · Cash flow from operating activities amounted to SEK -37.3 million (-27.6) January – June 2018 · Net revenues for the period amounted to SEK 104.6 million (58.2) · Operating profit amounted to SEK 25.3 million (3.9) · Profit for the period